Percutaneous Endoscopic Tracheal Plug/Unplug for CDH
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Congenital diaphragmatic hernia is an anatomically simple birth defect in which contents of the fetal abdomen migrate into the chest due to incomplete formation of the diaphragm. Herniation of viscera into the chest prevents the fetal lungs from developing and growing to normal size. In the most severe cases, there is significant morbidity and mortality at birth. For these fetuses, fetal intervention may improve outcomes by enabling the lungs to grow enough in utero that they are capable of sustaining life after birth. This unblinded, non-randomized trial will assess the safety and efficacy of the use of the Goldvalve balloon and MiniTorquer microcatheter to perform percutaneous temporary tracheal occlusion to treat severe CDH in utero. The primary outcome variable will be fetal lung growth due to successful 'plugging/unplugging' of the trachea, as determined by serial lung-head ratio (LHR) measurements. Secondary outcome variables include maternal, fetal and neonatal variables, specifically neonatal survival at 90 days of life. For infants who survive beyond 90 days post-delivery, their families will be offered follow-up (up to 2 years of age and possibly beyond) in the Long-term Infant-to-Adult Follow-up Evaluation (LIFE) Clinic at UCSF.
| Condition | Intervention | Phase |
|---|---|---|
|
Severe Congenital Diaphragmatic Hernia |
Device: Percutaneous endoscopic fetal tracheal occlusion/unocclusion |
Phase 1 Phase 2 |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Percutaneous Endoscopic Tracheal Plug/Unplug for Congenital Diaphragmatic Hernia |
- Fetal lung growth due to successful fetal tracheal occlusion/unocclusion, as determined by serial LHR measurements [ Time Frame: Between 26 and 34 weeks gestation ] [ Designated as safety issue: Yes ]
- Neonatal survival at 90 days of life. [ Time Frame: 90 days post-delivery ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 10 |
| Study Start Date: | October 2008 |
| Estimated Study Completion Date: | December 2016 |
| Estimated Primary Completion Date: | September 2014 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Treatment
Percutaneous endoscopic fetal tracheal 'plug/unplug' using the Goldvalve balloon
|
Device: Percutaneous endoscopic fetal tracheal occlusion/unocclusion
Between 26-28 wks' gestation, percutaneous endoscopic placement of the tracheal balloon. Between 32-34 wks' gestation, percutaneous endoscopic removal of the balloon.
Other Name: Goldvalve Balloon and MiniTorquer Delivery Microcatheter
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | Yes |
General subject population: Pregnant women in the second trimester, at least 18 years of age, and of any and all ethnic backgrounds.
Inclusion Criteria:
- Confirmed diagnosis of CDH
- Normal fetal echocardiogram
- Normal karyotype
- Fetal liver herniated into the left hemithorax
- Lung-head ratio (LHR) is 1.0 or less, calculated between 24-26 weeks' gestation
- Fetus is between 26 and 28 weeks' gestation
- Singleton pregnancy
- Mother meets psychosocial criteria
- Pre-authorization from third-party payor for fetal intervention, or ability to self-pay.
Exclusion Criteria:
- Failure to meet all inclusion criteria
- Other congenital anomalies detected on ultrasound
- Contraindication to abdominal surgery or general anesthesia
- Allergy to latex
- Preterm labor, preeclampsia, or uterine anomaly (e.g., large fibroid tumor)
- Family unable or refuses to stay in San Francisco for duration of the tracheal occlusion period and for the duration of the pregnancy as medically necessary.
Contacts and Locations| Contact: Jody A Farrell, MSN, PNP | 415 476 0445 | fetus@ucsfmedctr.org |
| Contact: Tamara Ryan, ADN | 415 502 0173 | fetus@ucsfmedctr.org |
| United States, California | |
| University of California, San Francisco Fetal Treatment Center | Recruiting |
| San Francisco, California, United States, 94143 | |
| Contact: Jody A. Farrell, MSN, PNP 800-793-3887 fetus@ucsfmedctr.org | |
| Contact: Tamara Ryan, RN 415-502-0173 fetus@ucsfmedctr.org | |
| Principal Investigator: Hanmin Lee, MD | |
| Sub-Investigator: Larry Rand, MD | |
| Sub-Investigator: Ruth B Goldstein, MD | |
| Sub-Investigator: Roberta L Keller, MD | |
| Sub-Investigator: Shinjiro Hirose, MD | |
| Sub-Investigator: Barbara J Bratton, MSN, PNP | |
| Sub-Investigator: Doug Miniati, MD | |
| Principal Investigator: | Hanmin Lee, MD | University of California, San Francisco Fetal Treatment Center |
More Information
Additional Information:
Publications:
| Responsible Party: | Hanmin Lee, Principal Investigator, University of California, San Francisco |
| ClinicalTrials.gov Identifier: | NCT00768703 History of Changes |
| Other Study ID Numbers: | 10-01765, TO CDH |
| Study First Received: | October 6, 2008 |
| Last Updated: | May 15, 2013 |
| Health Authority: | United States: Food and Drug Administration United States: Institutional Review Board United States: UCSF Fetal Surgery Oversight Committee |
Keywords provided by University of California, San Francisco:
|
Congenital diaphragmatic hernia lung-head ratio percutaneous tracheal occlusion fetal intervention |
Additional relevant MeSH terms:
|
Hernia Hernia, Diaphragmatic Hernia, Hiatal Pathological Conditions, Anatomical |
ClinicalTrials.gov processed this record on May 19, 2013